Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca
alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy …

With a 3‐fold increase in the number of cancer survivors noted since the 1970s, there are
now over 28 million cancer survivors worldwide. Accordingly, there is a heightened …

Radiation therapy (RT) is the most effective single modality for local control of non-Hodgkin
lymphoma (NHL) and is an important component of therapy for many patients. Many of the …

The number of patients surviving≥ 5 years after initial cancer diagnosis has significantly
increased during the last decades due to considerable improvements in the treatment of …

Background The use of anthracycline chemotherapy is limited by the occurrence of
cardiotoxicity. In an effort to prevent this cardiotoxicity, different anthracycline derivates have …

Cardiovascular disease frequently occurs after lymphoma therapy, but it is common in the
general population too. Therefore, risk estimation requires comparison to population-based …

Haematopoietic stem cell transplantation (HCT) is the treatment of choice for defined
malignant and non‐malignant haematological disorders. The main drawbacks of HCT are …

BACKGROUND: A systematic overview and meta‐analysis of studies reporting data on
hypothyroidism (HT) after radiation therapy was conducted to identify risk factors for …

As a result of therapeutic advances, there is a growing population of survivors of both
Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). A thorough understanding …

Cancer is the second leading cause of death worldwide and is a major global health burden.
Significant improvements in survival have been achieved, due in part to advances in …